|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...120121122123124125126127128129130...156157» |
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy: A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2013
P3, N=453, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed
- pateclizumab (RG7416) / Roche
Enrollment change, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 21, 2013
P2, N=211, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=210210 --> 211
- Enrollment change: Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease (clinicaltrials.gov) - May 21, 2013
P4, N=35, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
N=210210 --> 211 N=70 --> 35
- Enrollment closed: Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease (clinicaltrials.gov) - May 21, 2013
P4, N=35, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
N=70 --> 35 Recruiting --> Active, not recruiting
- ||||| Orencia (abatacept) / BMS
Enrollment closed, Combination therapy, Monotherapy: AVERT: Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis (clinicaltrials.gov) - May 20, 2013
P3, N=348, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy (clinicaltrials.gov) - May 20, 2013
P3, N=592, Completed, Sponsor: Centocor, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- MDX-1342 / BMS
Enrollment change, Combination therapy: MDX1342-01: Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 20, 2013
P1, N=26, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=50 --> 26
- Trial completion: Safety of Polyphenon E in Multiple Sclerosis Pilot Study (clinicaltrials.gov) - May 20, 2013
P1, N=10, Completed, Sponsor: Louisiana State University Health Sciences Center in New Orleans
N=50 --> 26 Recruiting --> Completed
- | MDX-1342 / BMS
Trial completion, Combination therapy: MDX1342-01: Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 20, 2013
P1, N=26, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Suspended --> Completed
- prednisone / Generic mfg.
Enrollment change: Serologically Active, Clinically Stable Systemic Lupus Erythematosus (clinicaltrials.gov) - May 19, 2013
P2, N=154, Completed, Sponsor: New York University School of Medicine
Suspended --> Completed N=80 --> 154
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: SUNDIAL: A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 19, 2013
P3, N=578, Completed, Sponsor: Genentech
N=80 --> 154 Active, not recruiting --> Completed
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: LUNAR: A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis (clinicaltrials.gov) - May 19, 2013
P3, N=145, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P2 trial: Overnight Closed Loop Study in U.S. (clinicaltrials.gov) - May 16, 2013
P2, N=85, Recruiting, Sponsor: Medtronic Diabetes
- metformin / Generic mfg.
Trial completion: The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 16, 2013
P4, N=42, Completed, Sponsor: Odense University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - May 15, 2013
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Plivensia (sirukumab) / J&J
New P3 trial: SIRROUND-LTE: Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 (clinicaltrials.gov) - May 15, 2013
P3, N=2165, Recruiting, Sponsor: Janssen Research & Development, LLC
- |||| ISIS 353512 / Ionis
Trial completion: Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis (clinicaltrials.gov) - May 15, 2013
P2, N=51, Completed, Sponsor: Isis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: REFINE: Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - May 14, 2013
P2, N=291, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Monotherapy: SELECT: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - May 14, 2013
P2, N=621, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion, Head-to-Head: Abatacept Versus Adalimumab Head-to-Head (clinicaltrials.gov) - May 14, 2013
P3, N=869, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Enrollment open: Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents (clinicaltrials.gov) - May 13, 2013
P4, N=144, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Occupational Therapy in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 13, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open, Real-world evidence, Real-world: Good EULAR Response In Patients With Early Rheumatoid Arthritis (clinicaltrials.gov) - May 13, 2013
P4, N=150, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial withdrawal: Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells (clinicaltrials.gov) - May 12, 2013
P1/2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Enrollment change: Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells (clinicaltrials.gov) - May 12, 2013
P1/2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Terminated --> Withdrawn N=10 --> 0
- | remtolumab (ABT-122) / AbbVie
New P1 trial: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2013
P1, N=24, Active, not recruiting, Sponsor: AbbVie
- ||||| Lantus (insulin glargine) / Sanofi
Enrollment closed: EDITION JP I: Comparison of a New Formulation of Insulin Glargine With Lantus (clinicaltrials.gov) - May 12, 2013
P3, N=240, Active, not recruiting, Sponsor: Sanofi
N=10 --> 0 Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia (clinicaltrials.gov) - May 9, 2013
P=N/A, N=70, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
Enrollment change: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - May 8, 2013
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=63 --> 40
- New P4 trial: Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops (clinicaltrials.gov) - May 8, 2013
P4, N=24, Completed, Sponsor: University of Sao Paulo General Hospital
- ||||| Careram (iguratimod) - Eisai, R / Pharm
New P4 trial: Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 8, 2013
P4, N=1108, Recruiting, Sponsor: Eisai Co., Ltd.
- | Benlysta (belimumab) / GSK
Enrollment open: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - May 8, 2013
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
N=63 --> 40 Not yet recruiting --> Recruiting
- ||| Trial completion: Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). (clinicaltrials.gov) - May 8, 2013
P=N/A, N=5383, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P1 trial: Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 7, 2013
P1, N=61, Completed, Sponsor: Sanofi
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy (clinicaltrials.gov) - May 7, 2013
P4, N=429, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- benfotiamine / Generic mfg.
Trial completion: Effects of Vitamin B1 in Type 1 Diabetic Patients (clinicaltrials.gov) - May 7, 2013
P1/2, N=67, Completed, Sponsor: University Hospital, Aker
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Combination therapy: Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2013
P2, N=465, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=156 --> 465
- Enrollment closed: Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica (clinicaltrials.gov) - May 6, 2013
P=N/A, N=150, Active, not recruiting, Sponsor: Lahey Clinic
N=156 --> 465 Recruiting --> Active, not recruiting
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2013
P2, N=465, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- gimsilumab (KIN-1901) / Roivant, Eisai
Trial initiation date: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - May 6, 2013
P1, N=19, Recruiting, Sponsor: Morphotek
Active, not recruiting --> Completed Initiation date: Jun 2010 --> May 2013
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Monotherapy: An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2013
P=N/A, N=130, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2010 --> May 2013 N=280 --> 130
- gimsilumab (KIN-1901) / Roivant, Eisai
Enrollment change: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - May 6, 2013
P1, N=19, Recruiting, Sponsor: Morphotek
N=280 --> 130 N=60 --> 19
- ||||| New P4 trial: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - May 6, 2013
P4, N=400, Active, not recruiting, Sponsor: Halozyme Therapeutics
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Monotherapy: A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Na (clinicaltrials.gov) - May 6, 2013
P3, N=318, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=60 --> 19 Recruiting --> Active, not recruiting
- ||||| New P2 trial: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - May 5, 2013
P2, N=158, Recruiting, Sponsor: University of Miami
- | Enrollment open: WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis (clinicaltrials.gov) - May 5, 2013
P3, N=360, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Nulojix (belatacept) / BMS
Trial withdrawal: Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients (clinicaltrials.gov) - May 5, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- | Biomarker, Trial completion: Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects (clinicaltrials.gov) - May 5, 2013
P=N/A, N=15, Completed, Sponsor: Orrin M Troum, M.D. and Medical Associates
Recruiting --> Withdrawn Recruiting --> Completed
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: ORAL1069: Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX (clinicaltrials.gov) - May 5, 2013
P3, N=968, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Withdrawn